Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Anetumab ravtansine (Primary) ; Cisplatin; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms ARCS-Multi
- Sponsors Bayer
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
- 01 Sep 2017 According to a Bayer media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.
- 19 Jun 2017 Status changed from not yet recruiting to recruiting.